Terms: = Kidney tumors AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
736 results:
1. A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.
Xu J; Zhang W; Tong J; Liu C; Zhang Q; Cao L; Yu J; Zhou A; Ma J
Cancer Immunol Immunother; 2024 Apr; 73(6):107. PubMed ID: 38642109
[TBL] [Abstract] [Full Text] [Related]
2. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract] [Full Text] [Related]
3. treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P; Grandal B; Jochum F; Bihan K; Coussy F; Barraud S; Asselain B; Dumas E; Sebbag C; Hotton J; Spaggiari E; Pierga JY; Savarino R; Laas E; Spano JP; Reyal F; Hamy AS
JAMA Netw Open; 2023 Oct; 6(10):e2339934. PubMed ID: 37883083
[TBL] [Abstract] [Full Text] [Related]
4. Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.
Wang H; Borlongan M; Hemminki A; Basnet S; Sah N; Kaufman HL; Rabkin SD; Saha D
Hum Gene Ther; 2023 Sep; 34(17-18):878-895. PubMed ID: 37578106
[TBL] [Abstract] [Full Text] [Related]
5. First-line ICIs in renal cell carcinoma.
Fiorentino V; Tralongo P; Larocca LM; Pizzimenti C; Martini M; Pierconti F
Hum Vaccin Immunother; 2023 Aug; 19(2):2225386. PubMed ID: 37395601
[TBL] [Abstract] [Full Text] [Related]
6. Rethinking Oncologic treatment Strategies with Interleukin-2.
Ko B; Takebe N; Andrews O; Makena MR; Chen AP
Cells; 2023 May; 12(9):. PubMed ID: 37174716
[TBL] [Abstract] [Full Text] [Related]
7. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
Raeber ME; Sahin D; Karakus U; Boyman O
EBioMedicine; 2023 Apr; 90():104539. PubMed ID: 37004361
[TBL] [Abstract] [Full Text] [Related]
8. Organ Transplants From Deceased Donors With Primary Brain tumors and Risk of Cancer Transmission.
Greenhall GHB; Rous BA; Robb ML; Brown C; Hardman G; Hilton RM; Neuberger JM; Dark JH; Johnson RJ; Forsythe JLR; Tomlinson LA; Callaghan CJ; Watson CJE
JAMA Surg; 2023 May; 158(5):504-513. PubMed ID: 36947028
[TBL] [Abstract] [Full Text] [Related]
9. Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and il2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
Eisner JR; Beebe KD; Mayhew GM; Shibata Y; Guo Y; Farhangfar C; Farhangfar F; Uronis JM; Mooney J; Milburn MV; Foureau D; White RL; Amin A; Milla ME
Cancer Res Commun; 2022 Aug; 2(8):894-903. PubMed ID: 36923304
[TBL] [Abstract] [Full Text] [Related]
10. Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma.
Jiang A; Ye J; Zhou Y; Zhu B; Lu J; Ge S; Qu L; Xiao J; Wang L; Cai C
Cells; 2023 Jan; 12(3):. PubMed ID: 36766692
[TBL] [Abstract] [Full Text] [Related]
11. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract] [Full Text] [Related]
12. Next Wave of Targets in the treatment of Advanced Renal Cell Carcinoma.
Cardenas LM; Deluce JE; Khan S; Gulam O; Maleki Vareki S; Fernandes R; Lalani AA
Curr Oncol; 2022 Jul; 29(8):5426-5441. PubMed ID: 36005167
[TBL] [Abstract] [Full Text] [Related]
13. New therapeutic strategies based on biasing il-2 mutants for cancers and autoimmune diseases.
Jin D; Jiang Y; Chang L; Wei J; Sun J
Int Immunopharmacol; 2022 Sep; 110():108935. PubMed ID: 35732097
[TBL] [Abstract] [Full Text] [Related]
14. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
Lu K; Chiu KY; Cheng CL
Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
[TBL] [Abstract] [Full Text] [Related]
15. Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal treatment Approaches over a 30-Year Period.
Bonetti E; Jenzer M; Nientiedt C; Kaczorowski A; Geisler C; Zschäbitz S; Jäger D; Hohenfellner M; Duensing S; Reimold P
Urol Int; 2022; 106(11):1158-1167. PubMed ID: 35477131
[TBL] [Abstract] [Full Text] [Related]
16. Coordinated Pembrolizumab and High Dose il-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer.
Chatzkel J; Schell MJ; Chahoud J; Zhang J; Jain R; Swank J; Ludlow S; Lombardi K; Lucas Y; Croft C; Rembisz J; Jameel G; Fishman M
Clin Genitourin Cancer; 2022 Jun; 20(3):252-259. PubMed ID: 35249821
[TBL] [Abstract] [Full Text] [Related]
17. Utilization of Treg Cells in Solid Organ Transplantation.
Juneja T; Kazmi M; Mellace M; Saidi RF
Front Immunol; 2022; 13():746889. PubMed ID: 35185868
[TBL] [Abstract] [Full Text] [Related]
18. Sea cucumber peptides inhibit the malignancy of NSCLC by regulating miR-378a-5p targeted TUSC2.
Mao J; Zhang Z; Chen Y; Wu T; Fersht V; Jin Y; Meng J; Zhang M
Food Funct; 2021 Dec; 12(24):12362-12371. PubMed ID: 34788772
[TBL] [Abstract] [Full Text] [Related]
19. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract] [Full Text] [Related]
20. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.
Hannan R; Mohamad O; Diaz de Leon A; Manna S; Pop LM; Zhang Z; Mannala S; Christie A; Christley S; Monson N; Ishihara D; Hsu EJ; Ahn C; Kapur P; Chen M; Arriaga Y; Courtney K; Cantarel B; Wakeland EK; Fu YX; Pedrosa I; Cowell L; Wang T; Margulis V; Choy H; Timmerman RD; Brugarolas J
Clin Cancer Res; 2021 Dec; 27(24):6716-6725. PubMed ID: 34551906
[TBL] [Abstract] [Full Text] [Related]
[Next]
